Physician profile
Basil E Chryssos
NPI 1851383517
$2,808.47
in general payments reported to CMS, 2019-2025
26 companies · $353 in 2025
The $353 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $546 · 2021: $196 · 2022: $329 · 2023: $331 · 2024: $270 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $902.84 | 2019-2024 | Rhythmia Mapping System, Watchman Access System, Rotablator Rotational Atherectomy System Console Kit |
| Janssen Pharmaceuticals, INC | $342.25 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $307.28 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $166.10 | 2019-2025 | |
| Pfizer INC. | $147.62 | 2019-2025 | |
| Amgen INC. | $124.21 | 2019-2025 | Repatha |
| Merck Sharp & Dohme LLC | $99.24 | 2021-2022 | |
| Abbott Laboratories | $87.99 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.12 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $74.65 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.08 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $56.73 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $53.60 | 2024-2025 | Lifevest |
| Heartflow, INC. | $37.39 | 2022 | |
| Amarin Pharma, INC. | $34.37 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $33.47 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $32.11 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $24.63 | 2024 | Opsumit, Uptravi |
| Lexicon Pharmaceuticals, INC. | $22.40 | 2024 | |
| Sanofi-Aventis U.S. LLC | $19.25 | 2019 | |
| Esperion Therapeutics, INC. | $18.86 | 2022 | |
| Novo Nordisk INC | $18.62 | 2025 | Wegovy |
| Lundbeck LLC | $18.22 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.78 | 2019 | |
| Bridgebio Pharma, INC. | $14.16 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, Ltd. | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basil Chryssos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.